专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

DK2825192T3 PROTEIN TIL FREMME AF VÆKST AF BLODKAR OG ANVENDELSER DERAF 未知
公开(公告)号：DK2825192T3
公开(公告)日：2019-09-02
申请号：DK13713309
申请日：2013-03-15
申请人： UNIV GEORGIA STATE RES FOUND , LIU ZHI REN , LI LIANGWEI , ZHANG YINWEI
发明人： LIU ZHI-REN , LI LIANGWEI , ZHANG YINWEI
IPC分类号： A61K38/45

2. 发明专利

AU2016203988A1 PROTEIN TO PROMOTE BLOOD VESSEL GROWTH AND USES THEREOF 未知
公开(公告)号：AU2016203988A1
公开(公告)日：2016-07-07
申请号：AU2016203988
申请日：2016-06-15
申请人： LI LIANGWEI , ZHANG YINWEI , LIU ZHI-REN , UNIV GEORGIA STATE RES FOUND
发明人： LI LIANGWEI , LIU ZHI-REN , ZHANG YINWEI
IPC分类号： A61K38/45
摘要： Abstract: The present application is directed to methods of promoting angiogenesis, including vascularizing an avascular site, or extending or enhancing existing vasculature comprising contacting tissue with a protein substantially similar to pyruvate kinase M2. The present application is also directed to proteins comprising pyruvate kinase M2 and pharmaceutical compositions comprising pyruvate kinase M2.

3. 发明专利

ES2743426T3 Proteína para inducir el crecimiento de vasos sanguíneos y usos de esta 未知
公开(公告)号：ES2743426T3
公开(公告)日：2020-02-19
申请号：ES13713309
申请日：2013-03-15
申请人： UNIV GEORGIA STATE RES FOUND , LIU ZHI REN , LI LIANGWEI , ZHANG YINWEI
发明人： LIU ZHI-REN , LI LIANGWEI , ZHANG YINWEI
IPC分类号： A61K38/45
摘要： Una proteína para uso en un método terapéutico para estimular la angiogénesis o el crecimiento de vasos sanguíneos en el tejido de un sujeto que comprende poner en contacto el tejido con la proteína, en la que la proteína es sustancialmente similar a la piruvato quinasa M2 y en la que la proteína está en forma dimérica.

4. 发明专利

AU2013231936A1 Protein to promote blood vessel growth and uses thereof 未知
公开(公告)号：AU2013231936A1
公开(公告)日：2014-09-25
申请号：AU2013231936
申请日：2013-03-15
申请人： LI LIANGWEI , LIU ZHI-REN , UNIV GEORGIA STATE RES FOUND , ZHANG YINWEI
发明人： LIU ZHI-REN , LI LIANGWEI , ZHANG YINWEI
IPC分类号： A61K38/45
摘要： A method for stimulating angiogenesis in a tissue of a mammal comprising contacting tissue with a protein substantially similar to pyruvate kinase M2.

5. 发明专利

AU2016203988B2 PROTEIN TO PROMOTE BLOOD VESSEL GROWTH AND USES THEREOF 未知
公开(公告)号：AU2016203988B2
公开(公告)日：2018-01-25
申请号：AU2016203988
申请日：2016-06-15
申请人： GEORGIA STATE UNIV RESEARCH FOUNDATION , LI LIANGWEI , LIU ZHI REN , ZHANG YINWEI
发明人： LI LIANGWEI , LIU ZHI-REN , ZHANG YINWEI
IPC分类号： A61K38/45
摘要： Abstract: The present application is directed to methods of promoting angiogenesis, including vascularizing an avascular site, or extending or enhancing existing vasculature comprising contacting tissue with a protein substantially similar to pyruvate kinase M2. The present application is also directed to proteins comprising pyruvate kinase M2 and pharmaceutical compositions comprising pyruvate kinase M2.

6. 发明专利

AU2013231936B2 Protein to promote blood vessel growth and uses thereof 未知
公开(公告)号：AU2013231936B2
公开(公告)日：2016-07-07
申请号：AU2013231936
申请日：2013-03-15
申请人： GEORGIA STATE UNIV RESEARCH FOUNDATION , LI LIANGWEI , LIU ZHI REN , ZHANG YINWEI
发明人： LIU ZHI-REN , LI LIANGWEI , ZHANG YINWEI
IPC分类号： A61K38/45
摘要： A method for stimulating angiogenesis in a tissue of a mammal comprising contacting tissue with a protein substantially similar to pyruvate kinase M2.

7. 发明申请

WO2007030802A2 TARGETED CONTRAST AGENTS AND METHODS FOR TARGETING CONTRAST AGENTS 审中-公开
标题翻译：针对对象代理的目标对象代理和方法
公开(公告)号：WO2007030802A2
公开(公告)日：2007-03-15
申请号：PCT/US2006035221
申请日：2006-09-08
申请人： UNIV GEORGIA STATE RES FOUND , YANG JENNY J , LIU ZHI-REN
发明人： YANG JENNY J , LIU ZHI-REN
IPC分类号： A61K49/16
CPC分类号： A61K49/14 , A61K49/085
摘要： A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.
摘要翻译：具有对比度蛋白质的造影剂具有对比性质和至少一种靶向部分，其中所述至少一种靶向部分可操作地连接或引入对比蛋白。包括靶向造影剂和制备这些药剂的方法。

8. 发明申请

WO2011050052A3 PROTEIN AGENT FOR DIABETES TREATMENT AND BETA CELL IMAGING 审中-公开
标题翻译：蛋白质类药物治疗糖尿病和β细胞成像
公开(公告)号：WO2011050052A3
公开(公告)日：2011-09-15
申请号：PCT/US2010053361
申请日：2010-10-20
申请人： UNIV GEORGIA STATE RES FOUND , LIU ZHI-REN , YANG JIE , XU BING , ZHOU WANGDA , XUE SHENGUI
发明人： LIU ZHI-REN , YANG JIE , XU BING , ZHOU WANGDA , XUE SHENGUI
IPC分类号： C07K19/00 , A61K38/26 , A61K49/14 , A61P3/10 , G01N33/52
CPC分类号： A61K38/26 , A61K38/00 , A61K47/60 , A61K49/085 , C07K14/605 , C07K2319/00
摘要： Glucagon-like peptide-1 (GLP-1 ) is a member of a large family of incretin hormones secreted in nutrient-dependent response. GLP-1 acts on GLP-1 receptor (GLP-1 R) that is highly expressed on pancreatic ß-cells. The peptide has great potential for development of diabetes treatment and diagnosis. However, the pharmaceutical effects of the peptide suffer from in vivo instability and short life due to degradation by Dipeptidylpeptidase-1 (DPP-4). The 30 amino acid peptide GLP-1 has been integrated into a stable host protein human calbindin D9k. The fusion protein binds to GLP-1 R as demonstrated by immunostaining analyses of GLP-1 R expressing cells. The fusion protein agents can be useful for both diabetes treatment and GLP-1 R receptor targeting MR imaging. The fusion protein has a size about 14 kDa, which enables efficient tissue penetration and retention, and an extended circulation time, is stable, remaining intact and retaining activity after 48 hours incubation with 75% human serum. The protein retains its native folded structure after boiling for ten minutes forming the basis of an experimental protocol for large scale production of the fusion protein (>30 mg/l bacterial culture). No toxicity has been observed with tests on mice. One aspect of the disclosure, therefore, provides a fusion protein comprising a first peptide characterized by selectively binding to a site of a target cell and linked to a second peptide, where the fusion protein is more stable than the first peptide alone. In embodiments of this aspect of the disclosure, the fusion protein may further comprise a detectable label attached thereto. In some embodiments of this aspect of the disclosure, the first peptide of the fusion protein may be glucagon-like peptide-1 (GLP-1 ), glucagon-like peptide-1 (GLP-1 )(7-36), or glucagon-like peptide-1 (GLP-1 ) (9-36), or a conservative variant thereof.
摘要翻译：胰高血糖素样肽-1（GLP-1）是营养物依赖性反应中分泌的肠降血糖素激素大家族的成员。 GLP-1作用于在胰岛β细胞上高表达的GLP-1受体（GLP-1R）。该肽具有发展糖尿病治疗和诊断的巨大潜力。然而，由于二肽基肽酶-1（DPP-4）的降解，肽的药物作用受到体内不稳定性和短寿命的影响。已将30个氨基酸的肽GLP-1整合到稳定的宿主蛋白人类钙结合蛋白D9k中。如通过表达GLP-1R的细胞的免疫染色分析所证实的，融合蛋白与GLP-1R结合。融合蛋白剂可用于糖尿病治疗和GLP-1R受体靶向MR成像。该融合蛋白具有约14kDa的大小，其使得有效的组织穿透和保留以及延长的循环时间是稳定的，在用75％人血清孵育48小时后保持完整并保持活性。沸腾10分钟后，蛋白质保留其天然折叠结构，形成大规模生产融合蛋白（> 30mg / l细菌培养物）的实验方案的基础。对小鼠的测试没有观察到毒性。因此，本公开的一个方面提供了包含第一肽的融合蛋白，所述第一肽的特征在于选择性结合靶细胞的位点并与第二肽连接，其中融合蛋白比单独的第一肽更稳定。在本公开内容的该方面的实施方案中，融合蛋白可以进一步包含与其连接的可检测标记。在本公开的该方面的一些实施方案中，融合蛋白的第一肽可以是胰高血糖素样肽-1（GLP-1），胰高血糖素样肽-1（GLP-1）（7-36）或胰高血糖素（GLP-1）（9-36）或其保守变体。

9. 发明申请

WO2007009058A3 CONTRAST AGENTS AND METHODS FOR PREPARING CONTRAST AGENTS 审中-公开
标题翻译：对比剂和制备对比剂的方法
公开(公告)号：WO2007009058A3
公开(公告)日：2007-04-19
申请号：PCT/US2006027327
申请日：2006-07-13
申请人： UNIV GEORGIA STATE RES FOUND , YANG JENNY J , LIU ZHI-REN
发明人： YANG JENNY J , LIU ZHI-REN
IPC分类号： A61B8/00
CPC分类号： A61K49/0002 , A61K49/0019 , A61K49/0056 , A61K49/14
摘要： Contrast agents comprising a scaffold protein having at least one operative integrated metal ion binding site.
摘要翻译：造影剂包含具有至少一个可操作的整合的金属离子结合位点的支架蛋白。

10. 发明公开

EP1901659A4 CONTRAST AGENTS AND METHODS FOR PREPARING CONTRAST AGENTS 有权
标题翻译：造影剂及其制造方法造影剂
公开(公告)号：EP1901659A4
公开(公告)日：2014-01-29
申请号：EP06787263
申请日：2006-07-13
申请人： UNIV GEORGIA STATE RES FOUND
发明人： YANG JENNY J , LIU ZHI-REN
IPC分类号： A61K49/00
CPC分类号： A61K49/0002 , A61K49/0019 , A61K49/0056 , A61K49/14
摘要： Contrast agents comprising a scaffold protein having at least one operative integrated metal ion binding site.
摘要翻译：造影剂，其包含具有至少一个操作集成金属离子结合位点的支架蛋白。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式